Biochemical Pharmacology 80 (2010) e1–e7

Contents lists available at ScienceDirect

Biochemical Pharmacology

journal homepage: www.elsevier.com/locate/biochempharm

Biochemical Pharmacology, Volume 80, issue 5, 1 September 2010

Contents

Editorial

Introduction to the Biochemical Pharmacology special issue on targeted cancer therapy 549

Keiran S.M. Smalley

Reviews and Article

Molecularly targeted therapy in hepatocellular carcinoma 550–560

Hung Huynh

Receptor tyrosine kinases presented on the cell membrane of tumor and endothelial cells and the intracellular signaling pathways are targets for antiangiogenic and antiproliferative agents.



BRAF as therapeutic target in melanoma 561–567

Claudia Wellbrock, Adam Hurlstone



doi:10.1016/S0006-2952(10)00423-5

Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics 568–574

Scott E. Woodman, Michael A. Davies



Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers 575–583

Stefan Duensing, Anette Duensing



Targeted therapy of chronic myeloid leukemia 584–591

Con Sullivan, Cong Peng, Yaoyu Chen, Dongguang Li, Shaoguang Li



Targeted therapy of thyroid cancer 592–601

Steven I. Sherman



The bone marrow microenvironment as a sanctuary for minimal residual disease in CML 602–612

Rajesh R. Nair, Joel Tolentino, Lori A. Hazlehurst



Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer 613–623

Takeshi Yoshida, Guolin Zhang, Eric B. Haura



Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail 624–637

Gajanan S. Inamdar, SubbaRao V. Madhunapantula, Gavin P. Robertson



Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma 638–646

Keith T. Flaherty, Igor Puzanov



Fine tuning chemotherapy to match BRCA1 status 647–653

Melissa Price, Alvaro N.A. Monteiro



Potential therapeutic implications of cancer stem cells in glioblastoma 654–665

Lin Cheng, Shideng Bao, Jeremy N. Rich



Exploiting the balance between life and death: Targeted cancer therapy and "oncogenic shock" 666–673

Sreenath V. Sharma, Jeff Settleman

Oncogene addiction can render cancer cells vulnerable to "oncogenic shock", a transient imbalance in pro-survival and pro-apoptotic signals acutely following oncoprotein inactivation.



Exploring death receptor pathways as selective targets in cancer therapy 674–682

Maria Russo, Annalisa Mupo, Carmela Spagnuolo, Gian Luigi Russo



Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer 683–689

Chunling Yi, Jasna Maksimoska, Ronen Marmorstein, Joseph L. Kissil



Notch signaling: Emerging molecular targets for cancer therapy 690–701

Ling Yin, Omaida C. Velazquez, Zhao-Jun Liu



Striking the target in Wnt-y conditions: Intervening in Wnt signaling during cancer progression 702–711

Tura C. Camilli, Ashani T. Weeraratna

Small molecule modulation of HH-GLI signaling: Current leads, trials and tribulations 712–723

Christophe Mas, Ariel Ruiz i Altaba



Current strategies to target p53 in cancer 724–730

Fang Chen, Wenge Wang, Wafik S. El-Deiry



Molecular imaging and targeted therapies 731–738

David L. Morse, Robert J. Gillies

Types of therapy biomarkers

Response: Used to measure a quantitative change in response to therapy.
Prognostic: Used to predict patient outcome regardless of therapy.
Predictive: Used to predict response to a specific therapy.

Imaging biomarkers

Anatomic: RECIST, volumetrics (CT, MRI).
Functional: Dynamic Contrast Enhanced-MRI, Diffusion MRI, Magnetization Transfer MRI, and Macromolecule contrast.
Molecular: PET (Receptors, metabolites, hypoxia, pH), CT/US/MR Nanoparticles, and MR (Spectroscopy, pH, hypoxia, chemical exchange saturation transfer, hyperpolarization).

Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling 739–747

Bin Fang, Eric B. Haura, Keiran S. Smalley, Steven A. Eschrich, John M. Koomen



Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray 748–754

David L. Morse, Yoga Balagurunathan, Galen Hostetter, Maria Trissal, Narges K. Tafreshi, Nancy Burke, Mark Lloyd, Steven Enkemann, Domenico Coppola, Victor J. Hruby, Robert J. Gillies, Haiyong Han



Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma **755–761**

Katherine L. Nathanson



The benefits and challenges associated with the use of drug delivery systems in cancer therapy **762–770**

Edna Cukierman, David R. Khan


During tumorigenesis the tumor-stroma is altered. These changes constitute both benefits and challenges for the use of drug delivery systems.

INDEXED/ABSTRACTED IN: *Curr. Cont. ASCA, Biosis Data, CAB Inter., Chemical Abstracts Service, Curr. Cont./Life Sci., CABS, EMBASE/Excerp. Med., Curr. Cont. ISI/BIOMED Database, MEDLINE, PASCAL-CNRS Data, Curr. Cont. Sci. Cit. Ind., Curr. Cont. SCISEARCH Data, Ind. Med., Reference Update. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/biochempharm